Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA.
Cancer Res. 2013 Feb 1;73(3):1128-41. doi: 10.1158/0008-5472.CAN-12-2731. Epub 2012 Dec 5.
Tumor-infiltrating immune cells can promote chemoresistance and metastatic spread in aggressive tumors. Consequently, the type and quality of immune responses present in the neoplastic stroma are highly predictive of patient outcome in several cancer types. In addition to host immune responses, intrinsic tumor cell activities that mimic stem cell properties have been linked to chemoresistance, metastatic dissemination, and the induction of immune suppression. Cancer stem cells are far from a static cell population; rather, their presence seems to be controlled by highly dynamic processes that are dependent on cues from the tumor stroma. However, the impact immune responses have on tumor stem cell differentiation or expansion is not well understood. In this study, we show that targeting tumor-infiltrating macrophages (TAM) and inflammatory monocytes by inhibiting either the myeloid cell receptors colony-stimulating factor-1 receptor (CSF1R) or chemokine (C-C motif) receptor 2 (CCR2) decreases the number of tumor-initiating cells (TIC) in pancreatic tumors. Targeting CCR2 or CSF1R improves chemotherapeutic efficacy, inhibits metastasis, and increases antitumor T-cell responses. Tumor-educated macrophages also directly enhanced the tumor-initiating capacity of pancreatic tumor cells by activating the transcription factor STAT3, thereby facilitating macrophage-mediated suppression of CD8(+) T lymphocytes. Together, our findings show how targeting TAMs can effectively overcome therapeutic resistance mediated by TICs.
浸润肿瘤的免疫细胞可以促进侵袭性肿瘤的化疗耐药和转移扩散。因此,肿瘤基质中存在的免疫反应的类型和质量高度预测了几种癌症类型患者的预后。除了宿主免疫反应外,与化疗耐药、转移扩散和免疫抑制诱导相关的内在肿瘤细胞活动也类似于干细胞特性。肿瘤干细胞远非静态的细胞群体;相反,它们的存在似乎受到高度动态过程的控制,这些过程依赖于肿瘤基质的信号。然而,免疫反应对肿瘤干细胞分化或扩增的影响还不太清楚。在这项研究中,我们表明通过抑制髓样细胞受体集落刺激因子-1 受体(CSF1R)或趋化因子(C-C 基序)受体 2(CCR2)来靶向浸润肿瘤的巨噬细胞(TAM)和炎性单核细胞,可以减少胰腺肿瘤中的肿瘤起始细胞(TIC)数量。靶向 CCR2 或 CSF1R 可提高化疗疗效、抑制转移并增强抗肿瘤 T 细胞反应。肿瘤诱导的巨噬细胞还通过激活转录因子 STAT3 直接增强胰腺肿瘤细胞的肿瘤起始能力,从而促进巨噬细胞介导的 CD8+T 淋巴细胞抑制。总之,我们的研究结果表明,如何靶向 TAMs 可以有效地克服由 TIC 介导的治疗耐药性。
Cancer Res. 2018-1-4
Essays Biochem. 2025-5-26
J Exp Clin Cancer Res. 2025-5-16
Front Med (Lausanne). 2025-4-30
ACS Med Chem Lett. 2011-10-5
Nat Rev Immunol. 2012-3-22